期刊文献+

嗜酸性细胞化生与桥本氏甲状腺炎癌变关系的初步研究 被引量:3

Relationship of eosinophil cells metaplasia with Hashimotos thyroiditis canceration
原文传递
导出
摘要 目的:研究桥本氏甲状腺炎嗜酸性化生细胞中COX-2和Bcl-2表达与癌变的关系。方法:用免疫组织化学方法检测120例桥本氏甲状腺炎组织中嗜酸性化生细胞COX-2和Bcl-2的表达,将其中23例5年内癌变的桥本氏甲状腺炎病例与剩下的97例未癌变的桥本氏甲状腺炎病例中,嗜酸性化生细胞的COX-2和Bcl-2的表达比较,分析嗜酸性化生细胞与桥本氏甲状腺炎癌变风险的关系。结果:COX-2和Bcl-2几乎在所有的桥本氏甲状腺炎嗜酸性化生细胞中均有表达,但表达强弱不一;在5年内癌变的桥本氏甲状腺炎病例中,嗜酸性化生细胞的数量和COX-2和Bcl-2的表达明显高于未癌变病例,差异有统计学意义,P<0.05。结论:桥本氏甲状腺炎中嗜酸性化生细胞的数量以及COX-2和Bcl-2的表达程度与癌变有密切关系。 OBJECTIVE:To study the expressions and significance of COX-2 and Bcl-2 in Hashimotos thyroiditis eosinophil cells. METHODS: The expressions of COX-2 and Bcl-2 were detected in 120 examples of Hashimotos thyroiditis eosinophil cells with immunohistochemistry, the expressions in 23 examples of canceration Hashimotos thyroiditis were compared with the others, and the relationship between the expressions of COX-2 and Bcl-2 in eosinophil cells and the risk of Hashimotos thyroiditis canceration was analyzed. RESULTS: The expressions of COX-2 and Bcl-2 almost existed in all Hashimotos thyroiditis, but there were different expression levels. The expression levels of COX-2 and Bcl-2 in the canceration examples were more obviously strong than those in the no canceration examples, and there was a significant difference (P0.05). CONCLUSION:There is an intimate relation ship between the risk of canceration together with the quantity of eosinophil cells and the expression levels of COX-2 and Bcl-2 in Hashimotos thyroiditis.
出处 《中华肿瘤防治杂志》 CAS 2010年第19期1544-1546,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 甲状腺炎 自身免疫性/病理学 前列腺素内过氧化物合酶 原癌基因蛋白质C-BCL-2 嗜酸细胞 thyroiditis autoimmune/pathology prostaglandin endoperoxide synthase proto oncogene proteins c-bcl-2 eosinophils
  • 相关文献

参考文献3

二级参考文献15

  • 1韩冰,石玉枝,霍建民.三氧化二砷对肺腺癌细胞凋亡及肺耐药蛋白基因多药耐药蛋白基因表达的影响[J].中国实用内科杂志,2005,25(3):243-244. 被引量:7
  • 2张坚,徐卓群,胡强,仇学文,王志荣.选择性环氧合酶2抑制剂对人膀胱癌细胞T24增殖和凋亡的作用[J].癌症,2007,26(4):377-381. 被引量:10
  • 3时京,孔垂泽,刘贤奎,刘奔,张莹,孙志熙.Bcl-2基因在人膀胱癌细胞中表达对CTL凋亡诱导作用的影响[J].中华肿瘤防治杂志,2007,14(14):1073-1076. 被引量:3
  • 4[1]Strate S M,Lee E L,Childers J H.Occult papillary carcinoma of the thyroid with distant metastasis[J].Cancer,1984,54 (6):1093-1097.
  • 5[2]Hodgson H C,Button J,Solorzzano C C,et al.Thyroid Cancer:Is the Incidence Still Increasing?[J].Ann Surg Oncol,2004,11 (12):1093-1097.
  • 6[4]Sen L,Natasha A P,Joong J T,et al.Mitochondrially Targeted Bcl-2 and Bcl-xL chimeras elicit different apoptotic responses[J].Mol Cells,2007,24 (3):378-387.
  • 7[5]Wang S,Yang D,Lippman M E.Targeting Bcl-2 and Bcl-xL with nonpeptidic small-molecule antagonists[J].Semin Oncol,2003,30 (5 Suppl 16):133-142.
  • 8[6]江昌新,谭郁彬.内分泌器官肿瘤病理学和遗传学[M].北京:人民卫生出版社,2006:51-105.
  • 9[8]Boise L H,Gonzalez-Garcia M,Postema C E,et al.Bcl-X,a Bcl-2-related gene that function as a dominant regulator of apoptotic cell death[J].Cell,1993,74 (4):597-608.
  • 10[9]方德福,杨焕明.分子生物学前沿技术[M].北京:北京医科大学中国协和医科大学联合出版社,1997:124-145.

共引文献4

同被引文献25

  • 1俞建平,陈润浩,桂律,叶萱光.桥本氏病合并甲状腺乳头状腺癌[J].中国癌症杂志,2005,15(1):16-18. 被引量:9
  • 2朱晓丽,周晓燕,朱雄增.甲状腺乳头状癌中BRAF^(V599E)点突变与RET/PTC融合基因的检测[J].中华病理学杂志,2005,34(5):270-274. 被引量:30
  • 3Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carci- noma managed at the Mayo Clinic during six decades (1940- 1999) :ternporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients [J].World J Surg, 2002,26 (8) :879-885.
  • 4Rivera M, Ghossein RA, Schoder H, et al. Histopathologic char acterization of radioactive iodine-refractory fluorodeoxyglucose- positron emission tomography-positive thyroid carcinoma [J]. Cancer, 2008,113 ( 1 ) : 48-56.
  • 5Cunha LL, Ferreira RC, Mareello MA, et al. Clinical and patho logical implications of concurrent autoimmune thyroid disorders and papillary thyroid cancer [J]. J Thyroid Res, 2011, 2011: 387062.
  • 6Xing M. BRAF mutation in thyroid cancer[J]. Endocr Relat Cancer, 2005,12(2) :245-262.
  • 7Kebebew E,Weng J,Bauer J,et al. The prevalence and prognos- tic value of BRAF mutation in thyroid cancer [J]. Ann Surg, 2007,246(3) :466-471.
  • 8Antonelli A, Ferri C, Ferrari SM, et al. New targeted molecular therapies for dedifferentiated thyroid cancer[J]. J Oncol, 2010, 2010:921682.
  • 9Russel JP, Shinoara S, Melillo RM, et al. Tyrosine kinase oncopro- tein, RET/PTC3,indices the secretion of myeloid growth and chemo- tactic factors [J]. Oncogene,2003,22(29) :4569-4577.
  • 10Puxeddu E,Knauf JA,Sartor MA,et al. RET/PTC induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response [J]. Endocr Relat Cancer, 2005,12(2) :319-334.

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部